Aspirex mechanical thrombectomy system in the treatment of acute iliofemoral deep vein thrombosis
10.3760/cma.j.cn113855-20220728-00482
- VernacularTitle:Aspirex机械血栓清除在急性髂股静脉血栓治疗中的应用
- Author:
Jianlin LI
1
;
Baoheng WANG
;
Da HAN
;
Shiyong WU
;
Yiqun FU
;
Yanjun WANG
;
Yonggan ZHANG
;
Bo YANG
;
Xueli GUO
;
Yan SONG
Author Information
1. 郑州大学第一附属医院血管外科，郑州 450052
- Keywords:
Venous thrombosis;
Mechanical thrombolysis;
Catheter directed thrombolysis;
Postthrombosis syndrome
- From:
Chinese Journal of General Surgery
2023;38(2):118-122
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To evaluate percutaneous mechanical thrombectomy (PMT) using Aspirex device for treating acute iliofemoral deep vein thrombosis (IFDVT).Methods:The clinical and follow-up data of 68 patients with IFDVT at our institution from Jan 2019 to Jun 2021 was retrospectively analyzed.Results:Twenty-six patients who had received PMT combined with auxiliary catheter directed thrombolysis (CDT) were included into group A, and 42 patients received CDT alone were into group B.The final thrombus clearance rates were more than 50%, and the clinical efficacy of thrombolysis was achieved. Group A associated a significant reduction in lysis duration and UK dosage and hospital days and degree of detumescence after 24 h compared with group B,and all aforementioned differences were statistically significant. Hospitalization costs in group A were more than group B. At one year follow-up, there were no significant differences between the two groups in the cumulative prevalence post-thrombotic syndrome (PTS) and the Villalta score and primary patency (92.0% vs. 90.0% , χ2=0.059, P=0.807). Conclusions:The application of PMT using the Aspirex device for acute IFDVT was safe and effective, which could accelerate the clearance of thrombus, and reduce UK dosage, lysis duration, hospital days. However, it increased the hospitalization costs.
